Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab
SMARCA4-deficient non-small cell carcinoma is an aggressive neoplasm with poor outcome. Several studies have highlighted its immunochemistry, pathophysiology, and underlying mechanisms, but studies of its definite treatment are few. Here, we report on a 69-year-old male with heterogenous pathologica...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1131448/full |
| _version_ | 1827979316544143360 |
|---|---|
| author | Yun-Tzu Lin Chien-Feng Li Chien-Feng Li Chien-Feng Li Chien-Feng Li Hung-Chang Wu Hung-Chang Wu Yi-Hua Jan Yu-Hsuan Kuo Yu-Hsuan Kuo Yu-Hsuan Kuo |
| author_facet | Yun-Tzu Lin Chien-Feng Li Chien-Feng Li Chien-Feng Li Chien-Feng Li Hung-Chang Wu Hung-Chang Wu Yi-Hua Jan Yu-Hsuan Kuo Yu-Hsuan Kuo Yu-Hsuan Kuo |
| author_sort | Yun-Tzu Lin |
| collection | DOAJ |
| description | SMARCA4-deficient non-small cell carcinoma is an aggressive neoplasm with poor outcome. Several studies have highlighted its immunochemistry, pathophysiology, and underlying mechanisms, but studies of its definite treatment are few. Here, we report on a 69-year-old male with heterogenous pathological presentations of SMARCA4-deficient non-small cell carcinoma. He initially presented with neck lymphadenopathies. Immunohistochemistry staining and genomic profiling confirmed the diagnosis of SMARCA4-deficient non-small cell carcinoma. The patient responded well to immune checkpoint inhibitors with nivolumab. However, new lesions with various pathological presentations and various responses to nivolumab appeared during the treatment course. The patient survived more than 3 years from the initial diagnosis. This case shows the efficacy of nivolumab to treat SMARCA4-deficient non-small cell lung carcinoma. |
| first_indexed | 2024-04-09T21:35:20Z |
| format | Article |
| id | doaj.art-fe28fad2cd7243ffa25870165e8040e7 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-09T21:35:20Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-fe28fad2cd7243ffa25870165e8040e72023-03-27T04:30:17ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-03-011410.3389/fimmu.2023.11314481131448Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumabYun-Tzu Lin0Chien-Feng Li1Chien-Feng Li2Chien-Feng Li3Chien-Feng Li4Hung-Chang Wu5Hung-Chang Wu6Yi-Hua Jan7Yu-Hsuan Kuo8Yu-Hsuan Kuo9Yu-Hsuan Kuo10Department of Oncology, Chi-Mei Medical Center, Tainan, TaiwanDepartment of Pathology, Chi-Mei Medical Center, Tainan, TaiwanInstitute of Precision Medicine, National Sun Yat-sen University, Kaohsiung, TaiwanDepartment of Medical Research, Chi Mei Medical Center, Tainan, TaiwanNational Institute of Cancer Research, National Health Research Institutes, Tainan, TaiwanDepartment of Oncology, Chi-Mei Medical Center, Tainan, TaiwanCollege of Pharmacy and Science, Chia Nan University, Tainan, TaiwanACT Genomics Co. Ltd., Taipei, TaiwanDepartment of Oncology, Chi-Mei Medical Center, Tainan, TaiwanCollege of Pharmacy and Science, Chia Nan University, Tainan, TaiwanInstitute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, TaiwanSMARCA4-deficient non-small cell carcinoma is an aggressive neoplasm with poor outcome. Several studies have highlighted its immunochemistry, pathophysiology, and underlying mechanisms, but studies of its definite treatment are few. Here, we report on a 69-year-old male with heterogenous pathological presentations of SMARCA4-deficient non-small cell carcinoma. He initially presented with neck lymphadenopathies. Immunohistochemistry staining and genomic profiling confirmed the diagnosis of SMARCA4-deficient non-small cell carcinoma. The patient responded well to immune checkpoint inhibitors with nivolumab. However, new lesions with various pathological presentations and various responses to nivolumab appeared during the treatment course. The patient survived more than 3 years from the initial diagnosis. This case shows the efficacy of nivolumab to treat SMARCA4-deficient non-small cell lung carcinoma.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1131448/fullSMARCA4BRG1SWI/SNFlung cancernon-small cell lung carcinomacheck-point inhibitors |
| spellingShingle | Yun-Tzu Lin Chien-Feng Li Chien-Feng Li Chien-Feng Li Chien-Feng Li Hung-Chang Wu Hung-Chang Wu Yi-Hua Jan Yu-Hsuan Kuo Yu-Hsuan Kuo Yu-Hsuan Kuo Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab Frontiers in Immunology SMARCA4 BRG1 SWI/SNF lung cancer non-small cell lung carcinoma check-point inhibitors |
| title | Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab |
| title_full | Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab |
| title_fullStr | Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab |
| title_full_unstemmed | Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab |
| title_short | Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab |
| title_sort | case report heterogenous smarca4 deficient thoracic non small cell lung carcinoma with various responses to nivolumab |
| topic | SMARCA4 BRG1 SWI/SNF lung cancer non-small cell lung carcinoma check-point inhibitors |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1131448/full |
| work_keys_str_mv | AT yuntzulin casereportheterogenoussmarca4deficientthoracicnonsmallcelllungcarcinomawithvariousresponsestonivolumab AT chienfengli casereportheterogenoussmarca4deficientthoracicnonsmallcelllungcarcinomawithvariousresponsestonivolumab AT chienfengli casereportheterogenoussmarca4deficientthoracicnonsmallcelllungcarcinomawithvariousresponsestonivolumab AT chienfengli casereportheterogenoussmarca4deficientthoracicnonsmallcelllungcarcinomawithvariousresponsestonivolumab AT chienfengli casereportheterogenoussmarca4deficientthoracicnonsmallcelllungcarcinomawithvariousresponsestonivolumab AT hungchangwu casereportheterogenoussmarca4deficientthoracicnonsmallcelllungcarcinomawithvariousresponsestonivolumab AT hungchangwu casereportheterogenoussmarca4deficientthoracicnonsmallcelllungcarcinomawithvariousresponsestonivolumab AT yihuajan casereportheterogenoussmarca4deficientthoracicnonsmallcelllungcarcinomawithvariousresponsestonivolumab AT yuhsuankuo casereportheterogenoussmarca4deficientthoracicnonsmallcelllungcarcinomawithvariousresponsestonivolumab AT yuhsuankuo casereportheterogenoussmarca4deficientthoracicnonsmallcelllungcarcinomawithvariousresponsestonivolumab AT yuhsuankuo casereportheterogenoussmarca4deficientthoracicnonsmallcelllungcarcinomawithvariousresponsestonivolumab |